Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > First Pill For Obstructive Sleep Apnea Shows Promise In Phase 3 Study
Health and Wellness

First Pill For Obstructive Sleep Apnea Shows Promise In Phase 3 Study

Last updated: June 29, 2025 8:12 pm
Share
First Pill For Obstructive Sleep Apnea Shows Promise In Phase 3 Study
SHARE

The American Academy of Sleep Medicine has reported that approximately 26 percent of adults between the ages of 30 and 70 years suffer from obstructive sleep apnea (OSA). This condition, characterized by repeated pauses in breathing during sleep due to relaxed throat muscles obstructing the airway, can have serious consequences if left untreated. OSA can lead to sleep deprivation, daytime drowsiness, and an increased risk of chronic medical conditions such as high blood pressure, heart disease, and stroke.

Currently, treatment options for OSA focus on keeping the airway open to allow for uninterrupted breathing during sleep. These options include changes in sleep position, CPAP masks and machines that provide continuous positive airway pressure, mouthpieces that help keep the throat open, and in severe cases, surgical interventions. Weight loss can also be beneficial for those with OSA caused by obesity, as excess fatty tissue in the neck can contribute to airway blockage.

Recently, Apnimed, Inc. announced promising results from the SynAIRgy phase 3 clinical trial of their AD109 pill, a potential new treatment for OSA. The pill, a combination of aroxybutynin and atomoxetine, works to increase nerve signals that control the muscles in the upper airway, ultimately reducing the severity of OSA. Participants in the trial experienced significant reductions in their apnea-hypopnea index (AHI), a measure of OSA severity, with over half achieving a reduction in disease severity and a quarter achieving complete control of their OSA.

The positive results from the SynAIRgy trial have paved the way for Apnimed to submit a New Drug Application for AD109 to the FDA by early 2026. If approved, AD109 would be the first prescription pill specifically designed for obstructive sleep apnea, offering a new treatment option for the millions of adults in the U.S. who suffer from this condition. With the potential for improved treatment outcomes and increased comfort for OSA patients, AD109 represents a significant advancement in the management of this prevalent sleep disorder.

See also  STAT+: Those living near the ocean face greater microplastic risk, study finds
TAGGED:apneaObstructivephasepillpromiseShowsSleepStudy
Share This Article
Twitter Email Copy Link Print
Previous Article PHOTOS: Denver Pride Parade 2025 PHOTOS: Denver Pride Parade 2025
Next Article 8 Best Azelaic Acid Products for Clearing and Calming Skin 8 Best Azelaic Acid Products for Clearing and Calming Skin
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Florida Sheriff’s Deputy Accidentally Shoots Partner With Taser, on Video

Police Officer Tases Colleague in Florida Incident Deputy Accidentally Shoots Partner With Taser ... Resulting…

June 25, 2025

President Trump Issues Second Warning as Radical Judges Threaten to Block His Tariffs… But There is One Huge Development! |

Trump Sounds Alarm Over Tariff Legal Battles President Trump sent out a clarion call on…

June 2, 2025

Antisemitic Sign at Barstool Sports Bar Draws Outrage

In a Philadelphia bar owned by Dave Portnoy, founder of Barstool Sports, patrons who opt…

May 8, 2025

Fetterman's chief of staff leaves amid string of departures

Pennsylvania Senator John Fetterman's Chief of Staff Departure Marks Continued Turnover In a noteworthy development…

June 3, 2025

Barcelona and Real Madrid meet in 2025’s first El Clasico with a Spanish Super Cup trophy on the line

Meanwhile, the situation at Watford escalated with the dismissal of Xisco Munoz and the appointment…

January 10, 2025

You Might Also Like

Research shows that improved home ventilation can ease asthma symptoms, advance public health
Health and Wellness

Research shows that improved home ventilation can ease asthma symptoms, advance public health

October 31, 2025
Public Health Is Much More Than Vaccines
Health and Wellness

Public Health Is Much More Than Vaccines

October 31, 2025
NIH shuns studying racism and health. Its own research finds a link
Health and Wellness

NIH shuns studying racism and health. Its own research finds a link

October 31, 2025
As Medicaid work requirements loom, study finds links between coverage, better health and higher employment
Health and Wellness

As Medicaid work requirements loom, study finds links between coverage, better health and higher employment

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?